Carasent Crecimiento futuro

Future controles de criterios 4/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Carasent de 105.5% y 12.7% por año respectivamente. Se prevé que el BPA crezca en un 106.5% al año. Se espera que la rentabilidad financiera sea de 3.3% en 3 años.

Información clave

113.0%

Tasa de crecimiento de los beneficios

114.1%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Healthcare Services	27.6%
Tasa de crecimiento de los ingresos	12.8%
Rentabilidad financiera futura	1.9%
Cobertura de analistas	Low
Última actualización	29 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Carasent ASA's (OB:CARA) Intrinsic Value Is Potentially 73% Above Its Share Price

May 11

Is Carasent ASA (OB:CARA) Potentially Undervalued?

Mar 18

Is Now The Time To Look At Buying Carasent ASA (OB:CARA)?

Nov 22

Carasent's (OB:CARA) Solid Profits Have Weak Fundamentals

May 06

Returns Are Gaining Momentum At Carasent (OB:CARA)

Apr 29

Carasent ASA Beat Analyst Profit Forecasts, And Analysts Have New Estimates

Feb 13

There Are Reasons To Feel Uneasy About Carasent's (OB:CARA) Returns On Capital

Nov 24

Calculating The Intrinsic Value Of Carasent ASA (OB:CARA)

May 23

We Like These Underlying Trends At Carasent (OB:CARA)

Feb 28

What Type Of Shareholders Own The Most Number of Carasent ASA (OB:CARA) Shares?

Jan 24

Previsiones de crecimiento de beneficios e ingresos

OB:CARA - Estimaciones futuras de los analistas y datos financieros pasados (NOK Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	370	32	22	86	2
12/31/2025	320	14	2	63	1
12/31/2024	270	-3	-16	55	1
3/31/2024	251	-56	-61	-4	N/A
12/31/2023	244	-46	-74	-4	N/A
9/30/2023	235	-64	-86	-3	N/A
6/30/2023	227	-49	-83	10	N/A
3/31/2023	210	5	-71	27	N/A
12/31/2022	195	31	-58	34	N/A
9/30/2022	179	47	-40	37	N/A
6/30/2022	168	15	-29	36	N/A
3/31/2022	154	33	-3	47	N/A
12/31/2021	137	0	-6	32	N/A
9/30/2021	117	-33	-1	29	N/A
6/30/2021	98	-21	11	33	N/A
3/31/2021	83	-46	2	21	N/A
12/31/2020	71	-38	3	19	N/A
9/30/2020	64	-14	5	21	N/A
6/30/2020	58	-4	3	18	N/A
3/31/2020	52	3	1	15	N/A
12/31/2019	48	3	2	12	N/A
9/30/2019	44	2	2	11	N/A
6/30/2019	40	0	1	7	N/A
3/31/2019	35	-3	-3	2	N/A
12/31/2018	24	-7	-2	0	N/A
9/30/2018	14	12	30	31	N/A
6/30/2018	6	18	51	52	N/A
3/31/2018	N/A	19	52	52	N/A
12/31/2017	N/A	20	N/A	51	N/A
9/30/2017	25	128	N/A	-6	N/A
6/30/2017	79	131	N/A	-16	N/A
3/31/2017	136	139	N/A	-24	N/A
12/31/2016	194	142	N/A	-36	N/A
9/30/2016	205	3	N/A	-33	N/A
6/30/2016	234	56	N/A	-60	N/A
3/31/2016	259	56	N/A	-42	N/A
12/31/2015	305	61	N/A	-32	N/A
9/30/2015	322	-31	N/A	4	N/A
6/30/2015	307	-80	N/A	24	N/A
3/31/2015	314	-84	N/A	22	N/A
12/31/2014	294	-79	N/A	24	N/A
9/30/2014	255	2	N/A	25	N/A
6/30/2014	248	2	N/A	23	N/A
3/31/2014	246	3	N/A	23	N/A
12/31/2013	254	5	N/A	29	N/A
9/30/2013	256	7	N/A	28	N/A
6/30/2013	263	9	N/A	32	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que CARA sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2%).

Beneficios vs. Mercado: Se prevé que CARA sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que CARA sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (12.7% al año) de CARA crezcan más rápidamente que los del mercado Norwegian (2.2% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 12.7% al año) de CARA crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de CARA sea baja dentro de 3 años (3.3%).

Carasent Crecimiento futuro

Future controles de criterios 4/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased by 9.4% to kr29.00

Consensus EPS estimates upgraded to kr0.53 loss

Price target decreased by 12% to kr33.50

Price target decreased by 8.6% to kr37.00

Consensus forecasts updated

Price target decreased to kr40.50

Recent updates

Eg Norge A/S contemplates launching a voluntary cash offer to acquire Carasent ASA (OB:CARA) for NOK 1.4 billion.

Eg Norge A/S contemplates launching a voluntary cash offer to acquire Carasent ASA (OB:CARA) for NOK 1.4 billion.

First quarter 2024 earnings released: kr0.15 loss per share (vs kr0.01 loss in 1Q 2023)

Carasent ASA's (OB:CARA) 32% Jump Shows Its Popularity With Investors

New major risk - Share price stability

Carasent ASA Announces Changes to Its Board

Full year 2023 earnings: EPS exceeds analyst expectations

Chief Executive Officer recently bought kr1.4m worth of stock

Independent Director recently bought kr100k worth of stock

Full year 2023 earnings: EPS exceeds analyst expectations

Founder recently bought kr28m worth of stock

High number of new and inexperienced directors

Calculating The Fair Value Of Carasent ASA (OB:CARA)

Carasent ASA Announces Staffan Hanstorp Resigns as A Member of the Board of Directors

Carasent ASA to Report Fiscal Year 2023 Results on Mar 22, 2024

Chief Financial Officer recently bought kr165k worth of stock

Is It Too Late To Consider Buying Carasent ASA (OB:CARA)?

New minor risk - Share price stability

Carasent Asa Approves Dividend

Independent Director recently bought kr111k worth of stock

Upcoming dividend of kr1.84 per share

Price target decreased by 9.4% to kr29.00

Chief Executive Officer recently bought kr96k worth of stock

Carasent's (OB:CARA) Returns On Capital Are Heading Higher

Chief Executive Officer recently bought kr97k worth of stock

Second quarter 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates upgraded to kr0.53 loss

Carasent ASA's (OB:CARA) Intrinsic Value Is Potentially 73% Above Its Share Price

Price target decreased by 12% to kr33.50

First quarter 2023 earnings released: kr0.01 loss per share (vs kr0.32 profit in 1Q 2022)

Is Carasent ASA (OB:CARA) Potentially Undervalued?

Full year 2022 earnings released: EPS: kr0.39 (vs kr0.002 loss in FY 2021)

Price target decreased by 8.6% to kr37.00

Carasent ASA to Report Q1, 2023 Results on May 04, 2023

Is Now The Time To Look At Buying Carasent ASA (OB:CARA)?

High number of new and inexperienced directors

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Consensus forecasts updated

Price target decreased to kr40.50

Carasent ASA (OB:CARA) acquired HPI Health Profile Institute AB for SEK 35 million.

Carasent ASA Provides Earnings Guidance for the Third Quarter and Full Year 2022

Carasent Asa Announces That Johan Lindqvist to Step Down as Chairman of the Board

Price target decreased to kr44.50

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Price target decreased to kr46.50

Investor sentiment improved over the past week

Consensus forecasts updated

Price target decreased to kr48.50

Carasent's (OB:CARA) Solid Profits Have Weak Fundamentals

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Returns Are Gaining Momentum At Carasent (OB:CARA)

Dennis Höjer Informs that He Will Step Down as CEO of Carasent ASA

No independent directors

Full year 2021 earnings: EPS misses analyst expectations

Carasent ASA Beat Analyst Profit Forecasts, And Analysts Have New Estimates

Full year 2021 earnings: EPS misses analyst expectations

Price target decreased to kr54.00

Carasent ASA (OB:CARA) completed the acquisition of Medrave Software AB.

Carasent ASA (OB:CARA) agreed to acquire Medrave Software AB for approximately SEK 130 million.

There Are Reasons To Feel Uneasy About Carasent's (OB:CARA) Returns On Capital

Price target increased to kr61.00

Third quarter 2021 earnings released: kr0.28 loss per share (vs kr0.21 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS kr0.34 (vs kr0.14 loss in 2Q 2020)

Chief Financial Officer Lars Forsberg has left the company

Carasent ASA announced that it has received NOK 420.155987 million in funding from Cardigan Holdco S.à r.l.

Carasent ASA (OB:CARA) acquired Metodika AB for approximately SEK 110 million.

Calculating The Intrinsic Value Of Carasent ASA (OB:CARA)

First quarter 2021 earnings released: kr0.14 loss per share (vs kr0.01 profit in 1Q 2020)